Evans syndrome (ES) is a combination of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). 1 Treatment options include intravenous immunoglobulins (IVIG), corticosteroids, cyclosporine, vincristine, danazol, azathioprine, cyclophosphamide, plasmapheresis, rituximab and splenectomy. 2, 3 Only one-third of patients were free of disease at 3 years after a median of five modalities of therapy in a recent survey, with seven dead, 12% with active disease on treatment, and 12% with persistent disease. 4 Hematopoietic stem cell transplant (HSCT) has been used in a few cases of refractory ES. [5] [6] [7] [8] A 20 month-old boy presented with fever, anemia, bruising, petechiae and splenomegaly. Investigations showed: RBC 2 420 000/ml, MCV 84 fl, reticulocytes 366 000/ml, WBC 3780/ml, neutrophils 47%, platelets 26 000/ml, direct Coombs test þ þ þ , LDH 2476, bilirubin 1.72 mg/dl, AST 91, ALT 17. No autoantibodies (ANA, ASMA, LKM) were found. Bone marrow was normocellular with erythroid hyperplasia, and normal myeloid and platelet precursors.
There was no response to prednisolone (20 mg/kg per day; days 1-3). IVIG (1 g/kg per day; days 1-2) resulted in transient improvement of anemia and thrombocytopenia over 4 weeks. Prednisone (3 mg/kg/day) and IVIG were followed by transient response. Rituximab (375 mg/m 2 ) was given monthly for 4 months. Steroid dose was reduced from 3 to 2 mg/kg/day, and cyclosporine was introduced. Platelets increased to 70 000/ml but anemia did not recover. At 6 months after diagnosis, cyclophosphamide (1 g/kg) and mycophenolate mofetil (50 mg/kg/day) were administered without response. By the eighth month, platelet count was 50-75 000/ml, while the child remained transfusiondependent with 90 RBC units transfused over 9 months.
Allogeneic HSCT from his HLA-identical brother was performed after conditioning with melphalan (140 mg/m 2 ), thiotepa (10 mg/kg) and fludarabine (40 mg/m 2 /day Â 4). GVHD prophylaxis comprised cyclosporine and shortcourse MTX. 3.5 Â 10 8 bone marrow mononuclear cells/kg were infused on day 0. On day þ 18, engraftment was documented with mixed chimerism (donor 85%). Owing to persistent hemolysis and transfusion dependence, together with decreasing mixed chimerism (40% donor), three gradually increasing donor lymphocyte infusions (DLI) were performed: 1.6 Â 10 7 on day 40, 5 Â 10 7 on day 50, and 1 Â 10 8 on day 100. Mixed chimerism persisted (donor cells p60%); split with 100% recipient myeloid compartment and 100% donor T cells. AIHA progressively regressed and resolved.
At 25 months after HSCT, he is asymptomatic with normal blood count (Hb 14.6 g/dl, MCV 80 fl, platelets 236 000/ml), and is off immunosuppression. Persistent mixed chimerism (85% recipient) is evident, with 45% of the lymphocytes of donor origin.
Our observation that AIHA was controlled despite split chimerism is in keeping with a previous report. 6 Mixed chimerism can be stable and associated with GVHD and a GV-autoimmunity/immune deficiency effect. Split chimerism in patients cured of congenital immunedeficiency 9 suggests that persistence of donor lymphocytes may be enough to correct the immune defect -and thus also autoimmunity in ES. 
